An Overview of a Trial Exploring MEK162 in Advanced Biliary Cancer

April 26, 2017
Ghassan K. Abou-Alfa, MD

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the trial of MEK162 in combination with gemcitabine and cisplatin in patients with untreated advanced biliary cancer.